BioVersys AG
BIOV
Company Profile
Business description
BioVersys AG is a multi-asset, clinical-stage biopharmaceutical company. The company focuses on research and development of novel antibacterial products for serious life-threatening infections caused by multi-drug resistant (MDR) bacteria. The pipeline products of the company include BV100 - novel MoA, Alpibectir - novel potentiator MoA, BV200 - novel anti-virulence MoA, BV500 - novel series, and others.
Contact
Sector
Healthcare
Stock type
Industry
Biotechnology
Fiscal Year End
Employees
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 7,913.90 | 352.20 | 4.66% |
| CAC 40 | 7,126.02 | 263.00 | 3.83% |
| DAX 40 | 20,562.73 | 891.85 | 4.53% |
| Dow JONES (US) | 39,435.55 | 1,172.90 | -2.89% |
| FTSE 100 | 7,913.25 | 233.77 | 3.04% |
| HKSE | 20,681.78 | 417.29 | 2.06% |
| NASDAQ | 16,371.34 | 753.63 | -4.40% |
| Nikkei 225 | 34,609.00 | 2,894.97 | 9.13% |
| NZX 50 Index | 12,201.43 | 394.88 | 3.34% |
| S&P 500 | 5,258.24 | 198.66 | -3.64% |
| S&P/ASX 200 | 7,709.60 | 334.60 | 4.54% |
| SSE Composite Index | 3,223.64 | 36.83 | 1.16% |